Corrigendum re “Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex” [Eur Urol Focus 2020;6:522–30]

In the original publication, the legend to Table 2 contained footnote letters without any corresponding indicators in the table body. The correct version of Table 2 is provided here.Table 2Effects table: input data for each of the favourable and unfavourable effects, the measurement metrics for each effect, and the data that were input to the MCDA model.ER = extended release; MCDA = multicriteria decision analysis; UTI = urinary tract infection; UUI = urgency urinary incontinence.Green identifies the drug with best favourable effect and red the drug with the worst unfavourable effect.Urgency: reduction from baseline in the frequency of a compelling desire to pass urine which is difficult to defer.Urgency urinary incontinence: reduction from baseline in the frequency of urgency incontinence episodes.Frequency: reduction from baseline in the frequency of wanting to pass urine in 24 h.Nocturia: reduction from baseline in the frequency of getting up at night to void.All unfavourable effects: proportion of patients experiencing the effect. Open table in a new tab ER = extended release; MCDA = multicriteria decision analysis; UTI = urinary tract infection; UUI = urgency urinary incontinence. Green identifies the drug with best favourable effect and red the drug with the worst unfavourable effect. Urgency: reduction from baseline in the frequency of a compelling desire to pass urine which is difficult to defer. Urgency urinary incontinence: reduction from baseline in the frequency of urgency incontinence episodes. Frequency: reduction from baseline in the frequency of wanting to pass urine in 24 h. Nocturia: reduction from baseline in the frequency of getting up at night to void. All unfavourable effects: proportion of patients experiencing the effect. Conflicts of interest: Christopher R. Chapple: grant, scientific study/trial, researcher, author, and meeting participant for Astellas Pharma; consultant/advisor for Galvani Bioelectronics (GSK); scientific study/trial and researcher for Ipsen; meeting participant and speaker for Pfizer; consultant/advisor for Pierre Fabre, Taris Biomedical, and Urovant Sciences; consultant/advisor and patent holder for Symimetic. Adrian Wagg has received funds for either research consultancy or speaker honoraria from Astellas Pharma, Essity Health and Hygiene AB, Pfizer Corp, Pfizer Canada, and Pierre Fabre. Ian Milsom has been an investigator and a speaker for Astellas and Pfizer, a speaker and consultant for Essity, and a speaker for Allergan and Pierre Fabre. Dirk De Ridder has been an investigator and a speaker for Astellas, a speaker for Neomedic, a trainer for Medtronic, and a consultant for Contura. Andrea Tubaro received consultancy fees from Allergan, Astellas, Boston Scientific, and Urovant; is a paid speaker for Pierre Fabre and an investigator for Bayer. Lawrence D. Phillips has received consultancy fees from Pfizer for other projects, as well as for many other pharmaceutical companies, though not on OAB; he acts solely as a process consultant, helping participants develop an MCDA model, but does not contribute to the content of the discussion; he declares no conflict of interest. Emma Mironska, Heinz Koelbl, and Dmitry Pushkar have no conflicts to declare. Funding/Support and role of the sponsor: This work was supported by an unrestricted educational grant to the European Association of Urology from Pierre Fabre and Pfizer, neither of whom were involved in the meeting or were involved in the writing or editing of this manuscript. Astellas Pharma contributed published data to the group to be considered for inclusion in the analysis. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom ComplexEuropean Urology FocusVol. 6Issue 3PreviewTake Home Message Traditional reporting of pharmacotherapy for overactive bladder (OAB) relies upon regulatory placebo-controlled studies. This is the first study using multicriteria decision analysis, which compares the placebo-controlled data for available OAB drugs. Full-Text PDF